Current research: Exosome Technologies Market Report- Growth with Top Companies Capricor, Codiak and Evox Therapeutics – WhaTech Technology and…

Exosome Technologies Market report is an in-depth research articulated by analysts by analyzing all the key factors such as regional market conditions, market boomers and decliners, opportunities, and size & scope of the market.

The research reports on Exosome Technologies Market report gives detailed overview of factors that affect global business scope. Exosome Technologies Market report shows the latest market insights with upcoming trends and breakdowns of products and services.

This report provides statistics on the market situation, size, regions and growth factors. Exosome Technologies Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.

Get FREE PDF Sample of the report @ http://www.reportsnreports.com/contactme=1781607

Top Company Profile Analysis in this Report

Capricor, Codiak and Evox Therapeutics

Exosome Technologies Market Report explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine and cerebrospinal fluid as well as in in vitro cell culture.

These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right. Research within this area remains in the nascent stages, although a number of clinical trials have been registered within the field.

Exosomes have several diverse therapeutic applications, largely centering on stem cell and gene therapy. Exosomes have been identified as endogenous carriers of RNA within the body, allowing for the intercellular transportation of genetic material to target cells.

As such, developers have worked to engineer exosomes for the delivery of therapeutic miRNA and siRNA-based gene therapies. As RNA is highly unstable within the body, a number of different biologic vector systems have been developed to enhance their transport within the circulation, including viruses and liposomes.

Similarly, exosomes derived from stem cells have also been identified for their therapeutic applications, particularly in the treatment of cancer and cardiovascular disease. Exosome technologies offer several advantages over existing biologic-based drug delivery systems.

They have a long circulatory half-life as a result of their high stability and ability to avoid breakdown by the mononuclear phagocyte system and reticuloendothelial systems. Moreover, exosomes have several functional properties that favor their use in therapeutic delivery.

Exosomes can be engineered to incorporate targeting ligands, allowing them to deliver cargo selectively to cells. Their small size allows them to penetrate the blood-brain barrier for the delivery of central nervous system therapies, whereas in cancer they can accumulate within the tumor via enhanced permeability and retention effects.

Finally, clinical trials have shown relatively large-scale production to be possible and indicate that exosome therapies can be safely administered to humans. Additionally, exosomes are being investigated for their potential as prognostic and diagnostic biomarkers for several different disease indications.

Exosomes make good candidates for biomarker research because of two unique characteristics: their presence in various accessible bodily fluids, and their resemblance to their parent cells of origin. R&D in exosome technologies has increased markedly in recent years.

This report provides detailed information on the various healthcare applications of exosomes, and assesses the pipeline, clinical trial and company landscapes.

Scope of this Report-

Reasons to accessthis Report-

Access Report-www.reportsnreports.com/purchasme=1781607

Table of Contents

1 Table of Contents 41.1 List of Tables 61.2 List of Figures 7

2 Exosomes in Healthcare 82.1 Overview of Exosomes 82.2 Drug Delivery Systems 92.2.1 Modified Release Drug Delivery Systems 92.2.2 Targeted Drug Delivery Systems 102.2.3 Liposomes 122.2.4 Viruses 142.2.5 Exosomes 172.3 The Exosome Lifecycle 182.4 Exosomes in Biology 182.5 Exosomes in Medicine 192.5.1 Biomarkers 192.5.2 Vaccines 202.6 Exosomes as a Therapeutic Target 202.7 Exosomes as Drug Delivery Vehicles 212.8 Therapeutic Preparation of Exosomes 212.8.1 Isolation and Purification 222.8.2 Drug Loading 222.8.3 Characterization 232.8.4 Bioengineering 232.8.5 Biodistribution and In Vivo Studies 232.8.6 Advantages of Exosome Therapies 242.8.7 Disadvantages of Exosome Therapies 242.9 Exosomes in Therapeutic Research 252.9.1 Exosome Gene Therapies 252.9.2 Exosome in Stem Cell Therapy 262.10 Exosomes in Oncology 272.10.1 Immunotherapy 272.10.2 Gene Therapy 282.10.3 Drug Delivery 292.10.4 Biomarkers 302.11 Exosomes in CNS Disease 302.11.1 Tackling the Blood-Brain Barrier 302.11.2 Exosomes in CNS Drug Delivery 312.11.3 Gene Therapy 322.12 Exosomes in Other Diseases 332.12.1 Cardiovascular Disease 332.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 363.1 Overview 363.2 Exosome Pipeline by Stage of Development and Molecule Type 363.3 Pipeline by Molecular Target 373.4 Pipeline by Therapy Area and Indication 383.5 Pipeline Product Profiles 383.5.1 AB-126 - ArunA Biomedical Inc. 383.5.2 ALX-029 and ALX-102 - Alxerion Biotech 393.5.3 Biologics for Autism - Stem Cell Medicine Ltd 393.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc. 393.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty 393.5.6 Biologic for Lysosomal Storage Disorder - Exerkine 393.5.7 Biologics for Prostate Cancer - Cells for Cells 403.5.8 CAP-2003 - Capricor Therapeutics Inc. 403.5.9 CAP-1002 - Capricor Therapeutics Inc. 413.5.10 CIL-15001 and CIL-15002 - Ciloa 423.5.11 ExoPr0 - ReNeuron Group Plc 423.5.12 MVAX-001 - MolecuVax Inc. 433.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences 443.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc. 443.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd 443.5.16 TVC-201 and TVC-300 - Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 484.1 Interventional Clinical Trials 484.1.1 Clinical Trials by Therapy Type 484.1.2 Clinical Trials by Therapy Area 494.1.3 Clinical Trials by Stage of Development 504.1.4 Clinical Trials by Start Date and Status 504.2 Observational Clinical Trials 514.2.1 Clinical Trials by Therapy Type 514.2.2 Clinical Trials by Therapy Area 514.2.3 Clinical Trials by Stage of Development 524.2.4 Clinical Trials by Start Date and Status 534.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 675.1 Company Profiles 675.1.1 Capricor Therapeutics Inc. 675.1.2 Evox Therapeutics Ltd 725.1.3 ReNeuron Group Plc 735.1.4 Stem Cell Medicine Ltd 775.1.5 Tavec Inc. 785.1.6 Codiak Biosciences Inc. 805.1.7 Therapeutic Solutions International Inc. 815.1.8 ArunA Biomedical Inc. 835.1.9 Ciloa 85

6 Appendix 866.1 References 866.2 Abbreviations 916.3 About GBI Research 936.4 Disclaimer 93

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more:

Current research: Exosome Technologies Market Report- Growth with Top Companies Capricor, Codiak and Evox Therapeutics - WhaTech Technology and...